Cynata Therapeutics Ord Shs V.CYP

Primary Symbol: CYYNF

Healthcare Biotechnology

Cynata Therapeutics Limited is an Australia-based clinical-stage stem cell and regenerative medicine company. The Company is focused on the development of therapies based on Cymerus, which is a therapeutic stem cell platform technology. Cymerus uses induced pluripotent stem cells and a precursor cell, mesenchymoangioblast (MCA) to manufacture cell therapy products, including mesenchymal stem cells, on a commercial scale. Its lead product candidate, CYP-001, is under Phase I trial and developed for the treatment of steroid-resistant acute graft-versus-host disease (GvHD). Clinical trials of Cymerus products in osteoarthritis, which is under Phase III trial, and diabetic foot ulcers (DFU) are ongoing. In addition, the Company has demonstrated the utility of its Cymerus technology in preclinical models of various diseases, including critical limb ischaemia, idiopathic pulmonary fibrosis, asthma, heart attack, sepsis, acute respiratory distress syndrome and other.

OTCPK:CYYNF - Post by User

Cynata Therapeutics Ord Shs > Valuation

<< Previous

Bullboard Posts

Next >>

Comment by yakattackon Apr 20, 2022 7:55pm

276 Views

Post# 34618545

RE:Valuation

Beaumont0150 wrote: More like new investors, stock way undervalued, get the word out is what's going on. SP should be much higher only 200M+ market cap.

5x higher MINIMUM considering the stage. I'd like to see more stressed on interviews/webinars about how this project should command a premium and why it's ridiculously priced at the moment. If we have to wait for "final" pilot results/NORAM.... fine but get on it then.

<< Previous

Bullboard Posts

Next >>

One of the strongest contenders to lead Canada’s cannabis market